Weight Loss/Weight Management (Obesity) - Market Insight, Epidemiology And Market Forecast - 2032

Weight Loss/Weight Management (Obesity) - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight's ""Obesity- Market Insights, Epidemiology, and Market Forecast-2032"" report delivers an in-depth understanding of the obesity, historical and forecasted epidemiology as well as the obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Obesity market report provides current treatment practices, emerging drugs, Obesity market share of the individual therapies, current and forecasted obesity market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Obesity Understanding and Treatment Algorithm

The DelveInsight’s Obesity market report gives a thorough understanding of the disease.Obesity is defined as an abnormal or excessive accumulation of fat or adipose tissue in the body that presents a risk to health. The body mass index (BMI) is used to define obesity, which is calculated as weight (kg)/height (m2). A person with a body mass index greater than or equal to 30 is considered obese. It is the second most common cause of preventable death, which has its association with the risk of development of inflammatory components, directly and indirectly, related to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. It imposes a significant public health epidemic that has progressively worsened over the past semi-centennial. An increase in obesity has been observed in children as well as adults of both genders and is prevalent in both developed and developing countries.

Compared to other chronic diseases, obesity results from an interaction between an individual’s genetic predisposition to weight gain and environmental influences. Gene discovery in the field of weight regulation and obesity has identified several major single-gene effects resulting in severe and early-onset obesity, as well as many more minor genes with more variable effects on weight and fat distribution, including age-of-onset and severity.

The most visible sign of obesity can be derived from the magnitude of excess adipose tissue fat, which is measured by taking anthropometric measurements such as body mass index (BMI), waist circumference, and others.

Body mass index, also known as Quetelet index, is defined as a person’s weight in kilograms divided by the square of his height in meters (kg/m2). For adults, a person is considered obese if they have BMI greater than or equal to 30. Whereas for children under 5 years of age, obesity is considered when weight-for-height is greater than three standard deviations above the WHO Child Growth Standards median. For children aged between 5–19 years of age, obesity is considered when weight-for-height is greater than two standard deviations above the WHO Growth Reference median

Diagnosis of obesity involves proper evaluation of the weight status, which considers many factors and uses various tools and diagnostic tests, including body mass index (BMI), waist circumference measurement, physical exams, and lab tests to check for comorbidities.


Losing weight through healthy eating, increasing physical activity, and making other lifestyle changes are all common therapies for obesity. Some people may benefit from weight-management programs in order to lose weight or avoid regaining it. Some obese persons are either unable to drop enough weight to enhance their health or are unable to maintain their weight loss. Other therapies, such as weight-loss drugs, gadgets, or bariatric surgery, may be considered in such circumstances.

Within the first 6 months of treatment, it is recommended to decrease 5–10% of the body weight. It can help reduce the risk of developing obesity-related health problems, and improve health conditions associated with obesity, such as high blood pressure and high cholesterol levels.

So obesity can be managed by reducing calories and adopting healthier eating habits, physical activity, and weight loss medications like orlistat and phentermine.

Obesity Epidemiology

The obesity epidemiology section provides insights about historical and current obesity patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2021, the total prevalent cases of obesity in adults (>19 years) were 182.22 Million (M) and in children (5–19 years) were 7.85 million in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

The disease epidemiology covered in the report provides historical as well as forecasted obesity epidemiology [segmented as total prevalent cases of obesity, total obesity patients seeking help, and total treated cases of obesity] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Obesity Epidemiology

The epidemiology segment also provides the obesity epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Obesity Drug Chapters

The drug chapter segment of the Obesity report encloses the detailed analysis of obesity marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the obesity clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for obesity treatment.

Obesity Market Outlook

The obesity market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted obesity market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, barriers, and demand for better technology.

This segment gives a thorough detail of obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the obesity market in 7MM is expected to witness a major change in the study period 2019–2032.

Key Findings

The obesity market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of obesity in the seven major markets is expected to increase during the study period (2019–2032). In 2021, the total market size of obesity was USD 1,052 million which is expected to rise during the study period (2019–2032).

The United States Market Outlook

The total market size of obesity in the United States accounted for USD 847 million in 2021 which is expected to rise during the study period (2019–2032).

EU-5 Countries: Market Outlook

In EU5, the total market size of obesity was USD 185 million in 2021, which is expected to rise during the study period (2019–2032).

Japan Market Outlook

In Japan, the total market size of obesity was USD 21 million in 2021, which is expected to rise during the study period (2019–2032).

Obesity Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the obesity market or expected to get launched in the market during the study period 2019-2032. The analysis covers obesity market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Obesity Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses obesity key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for obesity emerging therapies.

Reimbursement Scenario in Obesity

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the obesity domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or obesity market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the obesity Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of obesity, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the obesity epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for obesity are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the obesity market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global obesity market.
Report Highlights
  • In the coming years, the obesity market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence obesity R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for obesity. The launch of emerging therapies will significantly impact the obesity market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for obesity.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Obesity Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Obesity Pipeline Analysis
  • Obesity Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Obesity Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • Obesity Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Obesity Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the obesity drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the obesity total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings of the market across 7MM and which country will have the largest obesity market size during the forecast period (2019-2032)?
  • At what CAGR, the obesity market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the obesity market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the obesity market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

  • Epidemiology Insights:
    • What are the disease risk, burden, and regional/ethnic differences of obesity?
    • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
    • What is the historical obesity patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
    • What would be the forecasted patient pool of obesity in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
    • Where will be the growth opportunities in the 7MM concerning the patient population about obesity?
    • Out of all 7MM countries, which country would have the highest prevalent population of obesity during the forecast period (2019-2032)?
    • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

    • Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
      • What are the current options for the obesity treatment in addition to the approved therapies?
      • What are the current treatment guidelines for the treatment of obesity in the USA, Europe, and Japan?
      • What are the onesity marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
      • How many companies are developing therapies for the treatment of obesity?
      • How many therapies are in-development by each company for obesity treatment?
      • How many are emerging therapies in mid-stage, and late stage of development for obesity treatment?
      • What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the obesity therapies?
      • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
      • What are the clinical studies going on for obesity and their status?
      • What are the current challenges faced in drug development?
      • What are the key designations that have been granted for the emerging therapies for obesity?
      • What are the global historical and forecasted markets of obesity?
      Reasons to buy
      • The report will help in developing business strategies by understanding trends shaping and driving the obesity market
      • To understand the future market competition in the obesity market and Insightful review of the key market drivers and barriers
      • Organize sales and marketing efforts by identifying the best opportunities for obesity in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
      • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
      • Organize sales and marketing efforts by identifying the best opportunities for the obesity market
      • To understand the future market competition in the obesity market

1. Key Insights
2. Report Introduction
3. Obesity Market Overview at a Glance
3.1. Drug-class Share (%) Distribution of Obesity in 2019
3.2. Drug-class Share (%) Distribution of Obesity in 2032
4. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Signs and Symptoms
6.3. Risk Factors and Causes
6.4. Classification
6.5. Pathophysiology
6.5.1. Controlling Food Intake
6.5.2. Dysregulation of Lipid and Glucose Metabolism
6.5.3. Role of Adipocyte Inflammatory Secretagogues
6.6. Clinical Manifestations
6.7. Complications
7. Diagnosis
7.1. Diagnosis of Childhood Obesity
7.2. Diagnosis of Adolescent Obesity
7.3. Diagnosis of Morbid Obesity
7.4. Diagnosis of Metabolic Syndrome
7.5. Diagnostic Guidelines
7.5.1. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Diagnosis of Patients with Obesity
8. Treatment and Management
8.1. Treatment Algorithms
8.2. Treatment and Management Guidelines
8.2.1. The Endocrine Society Pharmacological Management of Obesity Guideline
8.2.2. European Society of Endocrinology Clinical Practice Guideline
8.2.3. The European Association for the Study of Obesity (EASO) Clinical Practice Guidelines
8.2.4. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale: 7MM
9.3. Epidemiology Scenario
9.3.1. Total Prevalent Cases of Obesity in the 7MM
10. Obesity: Country-wise Epidemiology
10.1. The United States
10.1.1. Total Prevalent Cases of Obesity in the United States
10.1.2. Total Obesity patients seeking help in the United States
10.1.3. Total Treated Cases of Obesity in the United States
10.2. EU5 (Germany, France, Italy, Spain, and United Kingdom)
10.2.1. Total Prevalent Cases of Obesity in EU-5
10.2.2. Total Obesity patients seeking help in EU-5
10.2.3. Total Treated Cases of Obesity in the EU-5
10.3. Japan
10.3.1. Total Prevalent Cases of Obesity in Japan
10.3.2. Total Obesity patients seeking help in Japan
10.3.3. Total Treated Cases of Obesity in Japan
11. Patient Journey
12. Marketed Therapies
12.1. Key Competitors: Marketed Drugs
12.2. Xenical (orlistat): Hoffmann-La Roche/H2 Pharma
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Other Developmental Activity
12.2.4. Clinical Development
12.2.5. Clinical Trials Information
12.2.6. Safety and Efficacy
12.2.7. Product Profile
12.3. Qsymia (Phentermine - Topiramate): Vivus/ IEH Biopharma
12.3.1. Product Description
12.3.2. Regulatory Milestones
12.3.3. Other Developmental Activity
12.3.4. Clinical Development
12.3.5. Clinical Trials Information
12.3.6. Safety and Efficacy
12.3.7. Product Profile
12.4. Contrave (Naltrexon-Bupropion): Orexigen Therapeutics/Currax
12.4.1. Product Description
12.4.2. Regulatory Milestones
12.4.3. Other Developmental Activity
12.4.4. Clinical Development
12.4.5. Clinical Trials Information
12.4.6. Safety and Efficacy
12.4.7. Product Profile
12.5. Saxenda (Liraglutide): Novo Nordisk
12.5.1. Product Description
12.5.2. Regulatory Milestones
12.5.3. Other Developmental Activity
12.5.4. Clinical Development
12.5.5. Clinical Trials Information
12.5.6. Safety and Efficacy
12.5.7. Product Profile
12.6. Wegovy (Semaglutide): Novo Nordisk
12.6.1. Product Description
12.6.2. Regulatory Milestones
12.6.3. Other Developmental Activity
12.6.4. Clinical Development
12.6.5. Clinical Trials Information
12.6.6. Safety and Efficacy
12.6.7. Product Profile
12.7. Imcivree (Setmelanotide): Rhythm Pharmaceuticals
12.7.1. Product Description
12.7.2. Regulatory Milestones
12.7.3. Other Developmental Activity
12.7.4. Clinical Development
12.7.5. Clinical Trials Information
12.7.6. Safety and Efficacy
12.7.7. Product Profile
13. Emerging Therapies
13.1. Key Competitors: Emerging Therapies
13.2. Key Competitors: Other Notable Emerging Therapies
13.3. Semaglutide oral: Novo Nordisk
13.3.1. Product Description
13.3.2. Clinical Development
13.3.3. Product Profile
13.4. Tirzepatide: Eli Lilly and Company
13.4.1. Product Description
13.4.2. Clinical Development
13.4.3. Clinical Trials Information
13.4.4. Safety and Efficacy
13.4.5. Product Profile
13.4.6. Analysts’ Views
13.5. Cotadutide: MedImmune
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.4. Clinical Trials Information
13.5.5. Safety and Efficacy
13.5.6. Product Profile
13.5.7. Analysts’ Views
13.6. BI 456906: Boehringer Ingelheim
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Clinical Trials Information
13.6.5. Safety and Efficacy
13.6.6. Product Profile
13.6.7. Analysts’ Views
13.7. RZL-012: Raziel Therapeutics
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Clinical Trials Information
13.7.5. Safety and Efficacy
13.7.6. Product Profile
13.7.7. Analysts’ Views
13.8. NNC0174-0833: Novo Nordisk
13.8.1. Product Description
13.8.2. Clinical Development
13.8.3. Clinical Trials Information
13.8.4. Safety and Efficacy
13.8.5. Product Profile
13.8.6. Analysts’ Views
13.9. Pemvidutide: Altimmune
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Clinical Trials Information
13.9.5. Safety and Efficacy
13.9.6. Product Profile
13.9.7. Analysts’ Views
13.10. Tesomet: Saniona
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Clinical Trials Information
13.10.5. Safety and Efficacy
13.10.6. Product Profile
13.10.7. Analysts’ Views
13.11. Xla1: YSOPIA Bioscience
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.11.4. Clinical Trials Information
13.11.5. Safety and Efficacy
13.11.6. Product Profile
13.11.7. Analysts’ Views
13.12. IBI362: Innovent Biologics
13.12.1. Product Description
13.12.2. Other Developmental Activities
13.12.3. Clinical Development
13.12.4. Clinical Trials Information
13.12.5. Safety and Efficacy
13.12.6. Product Profile
13.12.7. Analysts’ Views
13.13. HSG4112: Glaceum
13.13.1. Product Description
13.13.2. Clinical Development
13.13.3. Clinical Trials Information
13.13.4. Safety and Efficacy
13.13.5. Product Profile
13.13.6. Analysts’ Views
13.14. S-237648: Shionogi
13.14.1. Product Description
13.14.2. Clinical Development
13.14.3. Clinical Trials Information
13.14.4. Safety and Efficacy
13.14.5. Product Profile
13.14.6. Analysts’ Views
13.15. ARD-101: Aardvark Therapeutics
13.15.1. Product Description
13.15.2. Other Developmental Activities
13.15.3. Clinical Development
13.15.4. Safety and Efficacy
13.15.5. Product Profile
13.15.6. Analysts’ Views
13.16. LY 3437943: Eli Lilly and Company
13.16.1. Product Description
13.16.2. Clinical Development
13.16.3. Clinical Trials Information
13.16.4. Safety and Efficacy
13.16.5. Product Profile
13.16.6. Analysts’ Views
13.17. Leucine/sildenafil: NuSirt Biopharma
13.17.1. Product Description
13.17.2. Clinical Development
13.17.3. Clinical Trials Information
13.17.4. Safety and Efficacy
13.17.5. Product Profile
13.17.6. Analysts’ Views
13.18. MBL949: Novartis
13.18.1. Product Description
13.18.2. Clinical Development
13.18.3. Clinical Trials Information
13.18.4. Product Profile
13.19. TG103: CSPC Baike (Shandong) Biopharmaceutical
13.19.1. Product Description
13.19.2. Other Developmental Activities
13.19.3. Clinical Development
13.19.4. Clinical Trials Information
13.19.5. Product Profile
13.20. SHR20004: Jiangsu HengRui Medicine
13.20.1. Product Description
13.20.2. Clinical Development
13.20.3. Clinical Trials Information
13.20.4. Product Profile
13.21. CT-868: Carmot Therapeutics
13.21.1. Product Description
13.21.2. Other Developmental Activities
13.21.3. Clinical Development
13.21.4. Clinical Trials Information
13.21.5. Product Profile
13.22. PF-06882961: Pfizer
13.22.1. Product Description
13.22.2. Clinical Development
13.22.3. Clinical Trials Information
13.22.4. Product Profile
13.23. NNC0165-1875: Novo Nordisk
13.23.1. Product Description
13.23.2. Clinical Development
13.23.3. Clinical Trials Information
13.23.4. Product Profile
13.24. XW 003: Sciwind Biosciences
13.24.1. Product Description
13.24.2. Other Developmental Activities
13.24.3. Clinical Development
13.24.4. Clinical Trials Information
13.24.5. Product Profile
13.25. LY3502970: Eli Lilly and Company
13.25.1. Product Description
13.25.2. Clinical Development
13.25.3. Clinical Trials Information
13.25.4. Product Profile
13.26. EMP16-01: Empros Pharma
13.26.1. Product Description
13.26.2. Other Developmental Activities
13.26.3. Clinical Development
13.26.4. Clinical Trials Information
13.26.5. Safety and Efficacy
13.26.6. Product Profile
13.26.7. Analysts’ Views
13.27. NNC-0480-0389: Novo Nordisk
13.27.1. Product Description
13.27.2. Clinical Development
13.27.3. Clinical Trials Information
13.27.4. Product Profile
13.28. NNC0247 0829: Novo Nordisk
13.28.1. Product Description
13.28.2. Clinical Development
13.28.3. Clinical Trials Information
13.28.4. Product Profile
14. Conjoint Analysis
15. Obesity: 7 Major Market Analysis
15.1. Key Findings
15.2. Potential of Current and Emerging therapies
15.3. Market Size of Obesity in the 7MM
15.4. Market Size of Obesity by Therapies
15.5. Market Size in the United States
15.5.1. Total Market Size of Obesity
15.5.2. Market Size of Obesity by Therapies in the United States
15.6. Market Size in EU-5
15.6.1. Total Market Size of Obesity
15.6.2. Market Size of Obesity by Therapies
15.7. Market Size of Obesity in Japan
15.7.1. Total Market Size of Obesity
15.7.2. Market Size of Obesity by Therapies
16. Reimbursement and Market access
16.1. United States
16.2. Europe
16.3. Japan
17. KOL Views
18. Market Drivers
19. Market Barriers
20. SWOT Analysis
21. Unmet Needs
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings